Id-1 expression induces androgen-independent prostate cancer cell growth through activation of epidermal growth factor receptor (EGF-R)

Carcinogenesis. 2004 Apr;25(4):517-25. doi: 10.1093/carcin/bgh047. Epub 2003 Dec 19.

Abstract

The failure of prostate cancer treatment is largely due to the development of androgen independence, since the androgen depletion therapy remains the front-line option for this cancer. Previously, we reported that over-expression of the helix-loop-helix protein Id-1 was associated with progression of prostate cancer and ectopic expression of Id-1 induced serum-independent proliferation in prostate cancer cells. In the present study, we investigated if exogenous Id-1 expression in the androgen sensitive LNCaP cells had any effect on androgen-dependent cell growth and studied the molecular mechanisms involved. Using stable Id-1 transfectants, we found that expression of Id-1 was able to reduce androgen-stimulated growth and S phase fraction of the cell cycle in LNCaP cells, indicating that Id-1 may be involved in the development of androgen independence in these cells. The Id-1-induced androgen-independent prostate cancer cell growth was correlated with up-regulation of EGF-R (epidermal growth factor-receptor) and PSA (prostate specific antigen) expression, as confirmed by western blotting analysis and luciferase assays. In contrast, down-regulation of Id-1 in androgen-independent DU145 cells by its antisense oligonucleotides resulted in suppression of EGF-R expression at both transcriptional and protein levels. In addition, the results from immunohistochemistry study showed that Id-1 expression was significantly elevated in hormone refractory prostate cancer tissues when compared with the hormone-dependent tumours. Our results suggest that up-regulation of Id-1 in prostate cancer cells may be one of the mechanisms responsible for developing androgen independence and this process may be regulated through induction of EGF-R expression. Inactivation of Id-1 may provide a potential therapeutic strategy leading to inhibition of androgen-independent prostate cancer cell growth.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / pathology
  • Androgens / pharmacology*
  • Animals
  • Cell Division / drug effects
  • Cell Division / genetics
  • Cell Line, Tumor
  • Cell Nucleus / physiology
  • ErbB Receptors / genetics
  • ErbB Receptors / physiology*
  • Humans
  • Immunohistochemistry
  • Inhibitor of Differentiation Protein 1
  • Male
  • Mice
  • Mice, Nude
  • NF-kappa B / antagonists & inhibitors
  • Nitriles / pharmacology
  • Promoter Regions, Genetic
  • Prostatic Neoplasms / pathology*
  • Repressor Proteins*
  • Sulfones / pharmacology
  • Transcription Factors / genetics*
  • Transfection
  • Transplantation, Heterologous

Substances

  • 3-(4-methylphenylsulfonyl)-2-propenenitrile
  • Androgens
  • ID1 protein, human
  • Idb1 protein, mouse
  • Inhibitor of Differentiation Protein 1
  • NF-kappa B
  • Nitriles
  • Repressor Proteins
  • Sulfones
  • Transcription Factors
  • ErbB Receptors